James Crowley: Precision Cancer Therapy Advances
James Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn about a recent article by Beilei Liu et al. published in Signal Transduction and Targeted Therapy Journal:
“Emerging as the most fervently pursued research modalities are small molecule targeted agents including lipid nanoparticles, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy.
The successful application of CAR-T cell therapy by Carl June in 2011 and the FDA approval of Pembrolizumab and Nivolumab in 2014 for melanoma treatment highlighted the potential of cancer immunotherapy.
Preventive measures also evolved, as evidenced by the approval of the nine-valent Gardasil 9 vaccine, offering broader protection against HPV strains linked to cervical cancer.
In summary, much recent research has shown that gut microbiota is closely related to the occurrence and progression of tumors, as well as response to a variety of cancer therapies.
It is clear that studies on gut microbiota are essential for the prevention and treatment of cancer.
Overall, the future of precision cancer treatment will be diversified and integrated, combining traditional therapeutic methods with emerging technologies to offer patients a wider range of treatment choices.
These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort but the potential to impede disease progression.
The advantages, disadvantages, challenges, and representative drugs or clinical trials related to cancer treatments discussed herein are compiled in Table 7 which offers a comprehensive overview and comparison.”
Title: Exploring treatment options in cancer: tumor treatment strategies
Authors: Beilei Liu, Hongyu Zhou, Licheng Tan, Kin To Hugo Siu, Xin-Yuan Guan
Read the Full Article on Signal Transduction and Targeted Therapy Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 28, 2026, 17:27Volkmar Weissig: Cellular Uptake of Isolated Mitochondria and Its Implications for Mitochondrial Transfer
-
Mar 28, 2026, 17:25Alan Nurden: FNAIT Remains an Important Clinical Challenge in Inherited Bleeding Disorders
-
Mar 28, 2026, 17:24Michael Baria: Is PRP Disease Modifying in Osteoarthritis?
-
Mar 28, 2026, 17:07Wolfgang Miesbach: How Does Protein S Inhibition Restore Hemostasis in von Willebrand Disease?
-
Mar 28, 2026, 17:01Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
-
Mar 28, 2026, 16:56Sonia Wolf: Reproductive Outcomes in Women with Sickle Cell Disease
-
Mar 28, 2026, 16:42Kalpana Gupta Shekhawat: Low Ferritin and Its Impact on Dopamine Signaling
-
Mar 28, 2026, 16:34Seema Dawood: Acquired Platelet Dysfunction with Eosinophilia – Bleeding Despite Normal Platelet Count
-
Mar 28, 2026, 16:18Mohamed F Doheim: AI-Driven Stroke Triage Boosts Workflow and EVT Use Across Multicenter Network